What’s the biggest difference between EU and US medical device systems?
The EU and US both regulate medical devices, but they differ in structure and how rules are applied.
In the EU, the system is built around EU-wide rules (notably the EU Medical Device Regulation, MDR, and the In Vitro Diagnostic Regulation, IVDR). Manufacturers generally need conformity assessment involving an independent body (a notified body) before placing many devices on the market. [1]
In the US, the system is built around FDA oversight, where device risk determines the pathway (for example, premarket authorization/clearance for many devices). The FDA regulates labeling, manufacturing controls, and post-market obligations. [2]
How do risk categories drive approval pathways in each system?
In the US, risk classification is central: devices are typically placed into classes (Class I, II, III), with higher-risk devices facing more stringent premarket requirements than lower-risk ones. [2]
In the EU, risk still matters, but the practical pathway is shaped by the device classification under MDR/IVDR and the conformity assessment route (including notified body involvement where required). [1]
What does “conformity assessment” mean in the EU versus “FDA review” in the US?
EU conformity assessment is the process manufacturers use to demonstrate their device meets MDR/IVDR requirements before market entry, often with participation from a notified body for relevant device types. [1]
US FDA review depends on the device and its classification and can include different premarket mechanisms. FDA also enforces ongoing obligations through quality system requirements and post-market controls. [2]
Who checks the device before it’s sold: notified bodies vs the FDA
In the EU, notified bodies (independent third parties designated by EU member states) often play a major role in the conformity assessment process under MDR/IVDR. [1]
In the US, the FDA is the primary regulator conducting or reviewing the applicable premarket pathway and enforcing regulatory requirements through inspections and oversight. [2]
What changes if the device is an in vitro diagnostic (IVD)?
The EU has a dedicated framework for IVDs under the IVDR, with requirements that are separate from the MDR device rules. [1]
In the US, IVDs are also regulated under FDA’s medical device framework, with premarket requirements depending on how the product is classified and what it is used for. [2]
How do labeling, post-market surveillance, and safety reporting differ?
EU rules emphasize post-market monitoring and, for many devices, post-market surveillance expectations tied to MDR/IVDR obligations. [1]
US rules emphasize FDA oversight including quality system enforcement and post-market reporting obligations. [2]
Can a device be sold in both markets with one regulatory “package”?
Not usually. Even when a manufacturer follows the same core principles (safety, performance, quality), the documentation and the required steps differ between the EU pathways (MDR/IVDR and conformity assessment with notified bodies where applicable) and US FDA pathways and requirements. [1][2]
Which system is more demanding for high-risk devices?
Both increase scrutiny with higher risk, but they do it differently: the EU uses MDR/IVDR classification and conformity assessment routes, while the US uses FDA device class-based premarket pathways and FDA review. [1][2]
Practical questions people often ask next
What does my device classification mean in each system?
The EU MDR/IVDR classification may not map 1:1 to US FDA device class, so the same product can face different documentation and regulatory steps. [1][2]
What are the timelines to market?
Timelines depend on the pathway chosen, including notified body capacity in the EU and FDA premarket review timeline in the US. (Exact timing varies by device and submission type.) [1][2]
---
Sources
- Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)
- FDA - Medical Devices (regulation and oversight)